Article

Synergistic Anti-Tumor Efficacy Achieved by Reversing Drug Resistance through the Regulation of the Tumor Immune Microenvironment with IL-12 and Osimertinib Combination Therapy

2024-01-16

Abstract excerpt

Patients receiving osimertinib treatment typically develop resistance around the 10th month after initiation. The most common resistance mechanism is the C797S mutation. Competitive resistance mechanisms identified in T790M-deficient patients include MET amplification, HER2 amplification, aberrant FGFR signaling, BRAF mutation, abnormal activation of insulin-like growth factor 1 receptor (IGF1R), and downstream si...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f20336a7-a157-56eb-982c-122e12ac205b
DOI: 10.21203/rs.3.rs-3852006/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Synergistic Anti-Tumor Efficacy Achieved by Reversing Drug Resistance through the Regulation of the Tumor Immune Microenvironment with IL-12 and Osimertinib Combination TherapyDOI 10.21203/rs.3.rs-3852006/v1Read

Abnormal activation of NF-κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid-derived suppressor cells to shape the immunosuppressive tumor immune microenvironment.Semantic proximity Read

Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsSemantic proximity Read

Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.Semantic proximity Read

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor resistant tumors resulting in complete responsesSemantic proximity Read

Preclinical Evidence of STAT3 Inhibitor, Pacritinib, Overcomes Temozolomide Resistance via Down-Regulating miR-21-enriched Exosomes from M2 Glioblastoma-Associated MacrophagesSemantic proximity Read

Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization.Semantic proximity Read

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatmentSemantic proximity Read

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read

Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages.Semantic proximity Read

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.Semantic proximity Read

Reprogramming Tumor-Associated Macrophages To Reverse EGFRT790M Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat.Semantic proximity Read

IL-10R Inhibition Reprograms Tumor-Associated Macrophages and Reverses Drug Resistance in Multiple MyelomaSemantic proximity Read